Teva confirms efficacy and safety of Ajovy for prevention of migraine

Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month

Novartis tender offer for MorphoSys commences

The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months

Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.

Dr. Reddy's launches drug-free migraine management device Nerivio in Europe

Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India

Vericiguat works on a pathway not currently targeted by existing heart failure treatments

Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial

Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084

For the first-line treatment of certain patients with metastatic non-small cell lung cancer

AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer

Application based on results from the TROPION-Breast01 Phase III trial

Bio-Techne partners with Nikon Instruments for innovative spatial biology services

Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities

Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024